Granite Point Mortgage Trust Inc. Announces Dates for Second Quarter 2025 Earnings Release and Conference Call
To participate in the teleconference, approximately 10 minutes prior to the above start time please call toll-free (877) 407-8031, (or (201) 689-8031 for international callers) and ask to be joined into the Granite Point Mortgage Trust Inc. call. You may also listen to the teleconference live via the Internet at www.gpmtreit.com, in the Investors section under the News & Events link. For those unable to attend, a telephone playback will be available beginning August 6, 2025, at 1:00 p.m. ET through August 20, 2025, at 12:00 a.m. ET. The playback can be accessed by calling (877) 660-6853 (or (201) 612-7415 for international callers) and providing the Access Code 13754470. The call will also be archived on the company's website in the Investors section under the News & Events link.
About Granite Point Mortgage Trust Inc.
Granite Point Mortgage Trust Inc. is a Maryland corporation focused on directly originating, investing in and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. Granite Point is headquartered in New York, NY. Additional information is available at www.gpmtreit.com.
Additional Information
Stockholders of Granite Point and other interested persons may find additional information regarding the Company at the Securities and Exchange Commission's Internet site at www.sec.gov or by directing requests to: Granite Point Mortgage Trust Inc., 3 Bryant Park, 24th Floor, New York, NY 10036, telephone (212) 364-5500.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250722661221/en/
Contacts
Investors:
Chris Petta
Investor Relations
Granite Point Mortgage Trust Inc.
(212) 364-5500
investors@gpmtreit.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
29 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
US Equity Indexes Jump After July Inflation Boosts Fed Rate-Cut Expectations
US equity indexes jumped in midday trading Tuesday, with the Nasdaq Composite and S&P 500 hitting al
